Presented by LabRoots


Although immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some patients do not respond, or stop responding within the first year of therapy. Identifying the underlying mechanisms associated with these variable response rates remains an important open research challenge in clinical oncology.

Join this free webinar to learn how researchers are integrating cell sorting, RNA sequencing, ex-vivo phenotype profiling, and patient-derived xenografts to study the mechanisms of PD-L1 resistance in cancer.

With this webinar, you will:

  • Review how a multi-omics approach can be used to study the resistance mechanisms to therapies targeting immune checkpoint inhibitors.
  • Evaluate how new clinical research tools can uncover complexities of tumors and their ecosystems.


Who should attend

Researchers who want to integrate a multi-omics approach in their clinical studies on immune checkpoint inhibitor resistance will gain valuable insights. In addition, the webinar will benefit those who want to learn about new technologies for isolating and profiling tumor cells.



Moshe Sade Feldman (PhD) is an Instructor in Medicine and the Director of the Translational Cancer Immunology lab at Massachusetts General Hospital Cancer Center.
Russell Jenkins (MD, PhD) is Faculty, Harvard Medical School and Assistant Physician, Massachusetts General Hospital.